Federal Register / Vol. 75, No. 61 / Wednesday, March 31, 2010 / Notices 16149 

5630 Fishers Lane, rm. 1093), Rockville, 

MD 20857, 301–827–7001, FAX: 301– 

827–6776, e-mail: 

minh.doan@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512530. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On April 29, 2010, the 

committee will discuss the efficacy and 

safety of new drug application (NDA) 

21–242, artesunate rectal suppositories, 

submitted by the World Health 

Organization, for the proposed use as a 

single dose for the initial treatment of 

patients with acute malaria who cannot 

take medication by mouth and for 

whom injectable treatment is not 

available. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before April 15, 2010. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. to 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before April 7, 2010. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by April 8, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Minh Doan 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: March 25, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–7113 Filed 3–30–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice Of Amendment—OS ARRA 

Expansion of Research Capabilities To 

Study CE Complex Patients (R24) SEP 

Meeting 

With this correction notice, the 

Agency for Healthcare Research and 

Quality (AHRQ) informs the public of 

an amendment made to the notice 

subject mentioned above published on 

March 18, 2010 Vol. 75, No. 52, Second 

paragraph of pages 13 135–13136. 

The revised should read: ‘‘DATE: 

April 15–16, 2010 (Open on April 15 

from 8 a.m. to 8:15 am. and closed for 

the remainder of the meeting)’’. 

Dated: March 19, 2010. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2010–6784 Filed 3–30–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–2312–N] 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

Medicaid and CHIP Programs; Meeting 

of the CHIP Working Group—April 26, 

2010 

AGENCIES: Centers for Medicare & 

Medicaid Services (CMS), Department 

of Health and Human Services (DHHS); 

Employee Benefits Security 

Administration (EBSA), Department of 

Labor (DOL). 

ACTION: Notice. 

SUMMARY: This notice announces the 

first meeting of the Medicaid, Children’s 

Health Insurance Program (‘‘CHIP’’), and 

Employer-Sponsored Coverage 

Coordination Working Group (referred 

to as the ‘‘CHIP Working Group’’). The 

CHIP Working Group will meet to 

address objectives specified under 

section 311(b)(1)(C) of the Children’s 

Health Insurance Program 

Reauthorization Act of 2009. This 

meeting is open to the public. 

DATES: Meeting Date: Monday, April 26, 

2010 from 9 a.m. to 5 p.m., Eastern 

Standard Time (E.S.T.). 

Deadline for Registration without Oral 

Presentation: April 21, 2010, 12 p.m., 

E.S.T. 

Deadline for Registration of Oral 

Presentations: April 12, 2010 12 p.m., 

E.S.T. 

Deadline for Submission of Oral 

Remarks and Written Comments: April 

12, 2010 12 p.m., E.S.T. 

Deadline for Requesting Special 

Accommodations: April 12, 2010 12 

p.m., E.S.T. 

ADDRESSES: Meeting Location: The 

meeting will be held at the Omni 

Shoreham, 2500 Calvert Street, NW. at 

Connecticut Avenue in Washington, DC 

20008. 

Submission of Testimony: 

Testimonies should be mailed to Stacey 

Green, Designated Federal Official 

(DFO), Centers for Medicare & Medicaid 

Services, 7500 Security Boulevard, Mail 

stop C2–04–04, Baltimore, MD 21244– 

1850, or contact the DFO via e-mail at 

stacey.green@cms.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Stacey Green, DFO, Centers for 

Medicare & Medicaid Services, DHHS at 

(410) 786–6102, or Amy Turner, 


jlentini on DSKJ8SOYB1PROD with NOTICES